Preclinical Efficacy and Anti-Inflammatory Mechanisms of Action of the Bruton Tyrosine Kinase Inhibitor Rilzabrutinib for Immune-Mediated Disease
The Journal of immunology (1950), 2021-04, Vol.206 (7), p.1454-1468 [Peer Reviewed Journal]Copyright © 2021 by The American Association of Immunologists, Inc. ;Copyright © 2021 by The American Association of Immunologists, Inc. 2021 Copyright © 2021 by The American Association of Immunologists, Inc. ;ISSN: 0022-1767 ;EISSN: 1550-6606 ;DOI: 10.4049/jimmunol.2001130 ;PMID: 33674445
Full text available